Shantanu Narayen - Pfizer Lead Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Director
Mr. Shantanu Narayen is an Independent Director of Pfizer Inc., since September 27, 2013. Mr. Narayen is President and Chief Executive Officer and Director of Adobe Systems Incorporated, a producer of creative and digital marketing software. Prior to his appointment as CEO in December 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development. Director of Dell Inc. from 2009 until October 2013 and Director of Metavante Technologies Inc. from 2007 until 2009. President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world
Age: 55  Director Since 2019      
212 733-2323  www.pfizer.com
Narayen?s experience as Chairman, President and CEO of Adobe brings strong leadership and management skills to the Board, and his past roles in worldwide product development provide valuable global operations experience. He also serves as a member and Vice Chairman of USIndia Strategic Partnership Forum. His experiences as a director on other public boards provides a broad perspective on issues facing public companies and governance matters. Pfizer benefits from Mr. Narayen?s extensive knowledge in technology, product innovation and leadership in the digital marketing category through his experience in the technology industry. In addition, his deep knowledge and understanding of business risks through his leadership at a global technology company provide further insight and perspective to the Board.

Shantanu Narayen Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 0.0828 % which means that on every $100 spent on asset it made $0.0828 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 20.94 % implying that it generated $20.94 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 0.0008. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 Billion
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer Inc has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Bonnie BasslerRegeneron Pharmaceuticals
2016
Robert ScullyZoetis Inc
2013
Huda ZoghbiRegeneron Pharmaceuticals
2016
Sanjay KhoslaZoetis Inc
2013
Alan GarberVertex Pharmaceuticals Incorpor
2017
Ellen HoffingPerrigo Company Plc
2008
Herman MorrisPerrigo Company Plc
1999
Hans HaslerDr Reddys Laboratories
2016
Bruce CarterDr Reddys Laboratories
2008
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Donal OConnorPerrigo Company Plc
2014
Kalpana MorpariaDr Reddys Laboratories
2007
Theodore SamuelstoPerrigo Company Plc
2017
Gary CohenPerrigo Company Plc
2009
George SingRegeneron Pharmaceuticals
1988
Sridar IyengarDr Reddys Laboratories
2011
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Michael JandernoaPerrigo Company Plc
2007
Paul BisaroZoetis Inc
2015
Christine PoonRegeneron Pharmaceuticals
2010
Ravi BhoothalingamDr Reddys Laboratories
2000

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Currently Active Assets on Macroaxis

BCH   
Purchased few shares of
few hours ago
Traded for 253.02
BSV   
Purchased few shares of
few hours ago
Traded for 203.46
BCH   
Purchased few shares of
few hours ago
Traded for 253.02
BSV   
Purchased few shares of
few hours ago
Traded for 203.46
BTC   
Purchased one share of
few hours ago
Traded for 9696.71
 2017 2018 2019 2020 (projected)
Revenue Per Employee582.55 K580.6 K586.07 K655.69 K
Net Income Per Employee236.23 K120.7 K184.29 K156.65 K
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.
Please check Your Equity Center. Please also try CEO Directory module to screen ceos from public companies around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page